Skip to main content

Myelodysplastic syndromes, version 2.2015.

Publication ,  Journal Article
Greenberg, PL; Stone, RM; Bejar, R; Bennett, JM; Bloomfield, CD; Borate, U; De Castro, CM; Deeg, HJ; DeZern, AE; Fathi, AT; Frankfurt, O ...
Published in: J Natl Compr Canc Netw
March 2015

The NCCN Guidelines for Myelodysplastic Syndromes (MDS) comprise a heterogeneous group of myeloid disorders with a highly variable disease course that depends largely on risk factors. Risk evaluation is therefore a critical component of decision-making in the treatment of MDS. The development of newer treatments and the refinement of current treatment modalities are designed to improve patient outcomes and reduce side effects. These NCCN Guidelines Insights focus on the recent updates to the guidelines, which include the incorporation of a revised prognostic scoring system, addition of molecular abnormalities associated with MDS, and refinement of treatment options involving a discussion of cost of care.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

March 2015

Volume

13

Issue

3

Start / End Page

261 / 272

Location

United States

Related Subject Headings

  • Prognosis
  • Oncology & Carcinogenesis
  • Myelodysplastic Syndromes
  • Humans
  • Genetic Testing
  • Disease Management
  • Cost-Benefit Analysis
  • 4203 Health services and systems
  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Greenberg, P. L., Stone, R. M., Bejar, R., Bennett, J. M., Bloomfield, C. D., Borate, U., … National comprehensive cancer network, . (2015). Myelodysplastic syndromes, version 2.2015. J Natl Compr Canc Netw, 13(3), 261–272. https://doi.org/10.6004/jnccn.2015.0038
Greenberg, Peter L., Richard M. Stone, Rafael Bejar, John M. Bennett, Clara D. Bloomfield, Uma Borate, Carlos M. De Castro, et al. “Myelodysplastic syndromes, version 2.2015.J Natl Compr Canc Netw 13, no. 3 (March 2015): 261–72. https://doi.org/10.6004/jnccn.2015.0038.
Greenberg PL, Stone RM, Bejar R, Bennett JM, Bloomfield CD, Borate U, et al. Myelodysplastic syndromes, version 2.2015. J Natl Compr Canc Netw. 2015 Mar;13(3):261–72.
Greenberg, Peter L., et al. “Myelodysplastic syndromes, version 2.2015.J Natl Compr Canc Netw, vol. 13, no. 3, Mar. 2015, pp. 261–72. Pubmed, doi:10.6004/jnccn.2015.0038.
Greenberg PL, Stone RM, Bejar R, Bennett JM, Bloomfield CD, Borate U, De Castro CM, Deeg HJ, DeZern AE, Fathi AT, Frankfurt O, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Klimek V, Komrokji R, Kujawski LA, Maness LJ, O’Donnell MR, Pollyea DA, Scott B, Shami PJ, Stein BL, Westervelt P, Wheeler B, Shead DA, Smith C, National comprehensive cancer network. Myelodysplastic syndromes, version 2.2015. J Natl Compr Canc Netw. 2015 Mar;13(3):261–272.

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

March 2015

Volume

13

Issue

3

Start / End Page

261 / 272

Location

United States

Related Subject Headings

  • Prognosis
  • Oncology & Carcinogenesis
  • Myelodysplastic Syndromes
  • Humans
  • Genetic Testing
  • Disease Management
  • Cost-Benefit Analysis
  • 4203 Health services and systems
  • 3211 Oncology and carcinogenesis